Filtered By:
Source: Annals of Oncology
Therapy: Neoadjuvant Chemotherapy Therapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1 results found since Jan 2013.
298PTargeting CDCA3 to improve chemotherapy response in triple negative breast cancer patients
ConclusionsOur data highlight CDCA3 as a novel prognostic factor in TNBC that modulates sensitivity to chemotherapy. These findings point to the therapeutic potential of targeting CDCA3 in TNBC.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest.
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
